Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors

Details for Australian Patent Application No. 2005254659 (hide)

Owner Almirall Prodesfarma, SA

Inventors Garrido Rubio, Yolanda; Pages Santacana, Lluis Miquel; Taltavull Moll, Joan; Buil Albero, Maria Antonia; Dal Piaz, Vittorio; Gracia Ferrer, Jordi

Agent Davies Collison Cave

Pub. Number AU-A-2005254659

PCT Pub. Number WO2005/123692

Priority P 200401500 18.06.04 ES

Filing date 13 June 2005

Wipo publication date 29 December 2005

International Classifications

C07D 237/24 (2006.01) Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 409/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

Event Publications

11 January 2007 PCT application entered the National Phase

  PCT publication WO2005/123692 Priority application(s): WO2005/123692

19 January 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005254660-Reduced susceptibility towards pathogens, in particular oomycetes, such as downy mildew in lettuce and spinach

2005254658-Indole derivatives as histamine receptor antagonists